Syndax Pharmaceuticals Inc expected to post a loss of 99 cents a share - Earnings Preview

Syndax Pharmaceuticals

24/02/2024 01:02

* Syndax Pharmaceuticals Inc  SNDX.OQ   SNDX.O  is expected
to show no change in quarterly revenue when it reports 
results on February 27 for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Syndax Pharmaceuticals
Inc is
for a loss of 99 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Syndax
Pharmaceuticals Inc is $35.50​, above​ its last closing price
of $23.13. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.80       -0.80      -0.73     Beat    8.2
 Jun. 30 2023  -0.73       -0.73      -0.64     Beat    12.6
 Mar. 31 2023  -0.60       -0.60      -0.59     Beat    1​
 Dec. 31 2022  -0.65       -0.65      -0.62     Beat    4.4
 ​​Sep.        -0.64       -0.63      -0.58     Beat    8.7
 30 2022                                                
 Jun. 30 2022  -0.66       -0.64      -0.62     Beat    2.6​
 Mar. 31 2022  -0.63       -0.63      -0.63     Met     0.8
 Dec. 31 2021  0.23        0.28       1.81      Beat    550.3
 This summary was machine generated February 24 at 01:02 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)